50765-13-4

Usage

Uses

Used in Organic Synthesis:
(5-(Benzyloxy)-2-iodophenyl)methanol is utilized as a key building block in the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure allows for the creation of a wide range of molecules with potential applications in the medical field.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, (5-(benzyloxy)-2-iodophenyl)methanol serves as an essential component for the development of new drugs. Its structural properties enable the design and synthesis of molecules with specific therapeutic targets.
Used in Radiochemistry Applications:
The presence of the iodine atom in (5-(benzyloxy)-2-iodophenyl)methanol makes it a valuable compound for radiochemistry applications. Iodine is often used in radiotracers for medical imaging, and (5-(benzyloxy)-2-iodophenyl)methanol can be a starting point for the development of new radiopharmaceuticals.
Overall, (5-(benzyloxy)-2-iodophenyl)methanol has important applications in the production of diverse chemical and pharmaceutical products, contributing to the advancement of medical treatments and diagnostic tools.

Upstream product

• 50765-12-3 5-(benzyloxy)-2-iodobenzaldehyde 
• 50765-11-2 2-iodo-5-hydroxybenzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1700-30-7 (3-(benzyloxy)phenyl)methanol 
• 79678-37-8 methyl 3-(benzyloxy)benzoate 
• 99-06-9 3-Carboxyphenol 
• 1700-37-4 3-Benzyloxybenzaldehyde 

Downstream Products

• 50765-14-5 5-Benzyloxy-2-iodbenzylchlorid 
• 1392097-99-2 C₃₇H₅₈O₆Si₂ 
• 1392098-03-1 C₃₇H₅₈O₇Si₂ 
• 1392098-04-2 C₃₇H₅₈O₇Si₂ 
• 1392097-92-5 5-benzyloxy-2-iodobenzyl pivalate 
• 1383707-68-3 (E)-benzyl 2-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]acetate 
• 1383707-67-2 (Z)-benzyl 2-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]acetate 
• 1383707-78-5 (E)-1-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]propan-2-one 
• 1383707-76-3 (Z)-1-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]propan-2-one 
• 1383707-41-2 (E)-methyl 2-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]acetate 
• 1383707-40-1 (Z)-methyl 2-[5-(benzyloxy)isobenzofuran-1(3H)-ylidene]acetate 
• 50765-12-3 5-(benzyloxy)-2-iodobenzaldehyde 

Relevant academic research and scientific papers

Palladium-catalyzed intermolecular tandem cyclization reaction: a highly regioselective synthesis of functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds

A highly regioselective synthesis of functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds using a novel palladium-catalyzed tandem cyclization reaction is explored. During the reaction process, C-O, C-C and C-O bonds are sequentially formed in one pot via decarboxylative allenylpalladium formation, nucleophilic attack, arylpalladium addition and intramolecular nucleophilic attack.

Enantioselective Palladium-Catalyzed Heck-Heck Cascade Reactions: Ready Access to the Tetracyclic Core of Lycorane Alkaloids

A rapid and efficient access to a wide variety of enantiomerically enriched C-11b substituted lycorane analogues can be achieved via a catalytic asymmetric Heck-Heck 6-exo/6-endo cascade reaction in the presence of (R)-BINAP.

Phosphine/palladium-catalyzed syntheses of alkylidene phthalans, 3-deoxyisoochracinic acid, isoochracinic acid, and isoochracinol

In this study we used sequential catalysis-PPh3-catalyzed nucleophilic addition followed by Pd(0)-catalyzed Heck cyclization-to construct complex functionalized alkylidene phthalans rapidly, in high yields, and with good stereoselectivities (E/Z ratios of up to 1:22). The scope of this Michael-Heck reaction includes substrates bearing various substituents around the alkylidene phthalan backbone. Applying this efficient sequential catalysis, we accomplished concise total syntheses of 3-deoxyisoochacinic acid, isoochracinic acid, and isoochracinol.

Synthesis and antifungal properties of papulacandin derivatives

Derivatives of an antifungal agent that targets the β-(1,3)-D-glucan synthase, papulacandin D, were synthesized and tested for activity. The papulacandin D structure contains a challenging benzannulated spiroketal unit, which is introduced in a palladiumcatalyzed cross-coupling reaction of a glycal silanolate and an aryl iodide followed by an oxidative spiroketalization. Four different variants were made, differing in the nature of the acyl side chain with respect to the length, and in the number and stereochemistry of the double bonds. Moderate biological activity was observed for the derivatives with a side chain based on palmitic acid and linoleic acid.

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.